Autonomix Medical Inc (AMIX) Notizie

Form 8-K - Current report

Autonomix Medical, Inc. Finalizes Design of ASIC Microchip for Sensing Technology Catheter for Use in Humans, Continuing Progress Toward a U.S. Pivotal Trial in 2025

Design lock for ASIC microchip follows successful completion of in vivo preclinical and extensive bench testing...

Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell Series

Live video webcast on Wednesday, January 22nd at 4:00 PM ET THE WOODLANDS, TX, Jan. 15, 2025 (GLOBE...

Autonomix Medical, Inc. Announces Abstract Highlighting Preliminary Positive Clinical Results Accepted at The Society of Interventional Oncology (SIO) 2025 Annual Scientific Meeting

THE WOODLANDS, TX, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or...

Autonomix Medical, Inc. Announces U.S. Patent Granted Covering the Treatment of Cancerous Tumors and Cancer Related Pain with Company’s Proprietary Catheter-Based Technology

Growing global patent portfolio to over 120 patents with 80 issued patents and over 40 pending patent...

Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment

THE WOODLANDS, TX, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or...

Autonomix Medical, Inc. Drives Towards U.S. Pivotal Trial with Appointment of Vice President, Regulatory Affairs and Quality

Continued efforts to build team and infrastructure required to support clinical and regulatory initiatives in...

Autonomix Medical, Inc. Achieves Design Lock for RF Ablation Catheter Following Successful Completion of Animal Testing, Continuing Progress Toward a U.S. Pivotal Trial in 2025

First-in-class catheter-based sensing technology designed to sense neuronal signals that indicate pain or...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 8-K - Current report

Autonomix Medical, Inc. Announces Closing of $10.0 Million Underwritten Public Offering Including Partial Exercise of Over-Allotment Option

THE WOODLANDS, TX, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or...

Form 424B4 - Prospectus [Rule 424(b)(4)]

Form EFFECT - Notice of Effectiveness

Autonomix Medical, Inc. Announces Pricing of $9.0 Million Underwritten Public Offering

THE WOODLANDS, TX, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or...